Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fast Like EpiPen: Mylan Reaches Quick Settlement Over Medicaid Rebates

Executive Summary

$465m settlement with DOJ to resolve questions about EpiPen's classification is roughly the size of autoinjector's Medicaid and Medicare sales last year; Mylan expects to enter corporate integrity agreement.

You may also be interested in...



Medicare Part D Drug Price Policies May Offer Financial Trade-Offs

Higher manufacturer discounts required in donut hole under new budget law could offset somewhat by point-of-sale rebates in Part D, which are expected to be included in President Trump's FY 2019 budget proposal.

Medtech And US DoJ: EpiPen, Dermagraft Lead 2017 Payouts To Feds

US DoJ collected more than $1bn in penalties from device manufacturers this year, chiefly on false claims and manufacturing violations. Here is a roundup and sortable table of the payouts.

List Price Increase 'Incentives' Must Be Reversed, HHS Nominee Azar Says

Senate Finance Committee Democrats grill HHS Secretary nominee Alex Azar about his ability to foster solutions to high drug pricing given his industry background, as well as his support for alternative financing in Medicaid.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel